이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Tabula Rasa HealthCare 배당금

배당금 기준 확인 0/6

Tabula Rasa HealthCare 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.0%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$2.26
배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Jul 26

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Jun 28

We Discuss Why Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) CEO Compensation May Be Closely Reviewed

Jun 05

Tabula Rasa HealthCare, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 60% Above Its Share Price

Apr 02

Tabula Rasa HealthCare (NASDAQ:TRHC) Is Carrying A Fair Bit Of Debt

Mar 12

Update: Tabula Rasa HealthCare (NASDAQ:TRHC) Stock Gained 51% In The Last Three Years

Feb 19

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 TRHC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: TRHC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Tabula Rasa HealthCare 시장 대비 배당 수익률

TRHC 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (TRHC)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Healthcare Services)	1.0%
애널리스트 예측 (TRHC) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 TRHC 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 TRHC 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 TRHC 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: TRHC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Tabula Rasa HealthCare 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Tabula Rasa HealthCare, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO, President & Director exercised options and sold US$117k worth of stock

Price target increased by 14% to US$8.38

Consensus EPS estimates upgraded to US$1.33 loss

Tabula Rasa Healthcare, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023 and Full Year Ending December 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 11% to US$7.30

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to US$1.49 loss

Price target increased to US$6.33

Tabula Rasa Healthcare, Inc. Revises Preliminary Revenue Guidance for the Fourth Quarter 2022

Price target decreased to US$5.92

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa HealthCare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Tabula Rasa Healthcare, Inc. Names April Gill Chief Commercial Officer

Tabula Rasa HealthCare, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Tabula Rasa Healthcare, Inc. Announces Board Changes

Tabula Rasa Healthcare, Inc. Announces Executive Changes

Consensus forecasts updated

Price target increased to US$6.42

Tabula Rasa HealthCare, Inc. announces New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Price target increased to US$6.75

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.91 loss in 2Q 2021)

Indaba Capital Sends Letter to Demand for Inspection of Books and Records of Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Indaba Capital Management L P Sends a Letter to Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Revises Revenue Guidance for the Second Quarter Ended June 30, 2022

Price target decreased to US$5.71

Price target decreased to US$6.33

Continuing To Avoid Tabula Rasa HealthCare Inc.

Consensus revenue estimates fall by 25%

Does Tabula Rasa HealthCare (NASDAQ:TRHC) Have A Healthy Balance Sheet?

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$9.92

Insufficient new directors

Tabula Rasa HealthCare, Inc. to Report Q1, 2022 Results on May 05, 2022

Independent Director recently bought US$58k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Tom Cancro Joins Tabula Rasa Healthcare, Inc. as Chief Financial Officer

Now 22% undervalued after recent price drop

Tabula Rasa HealthCare, Inc. to Report Q4, 2021 Results on Feb 24, 2022

An unknown buyer agreed to acquire DoseMeRx Solution of Tabula Rasa HealthCare, Inc.

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Calculating The Fair Value Of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)

Co-President recently sold US$95k worth of stock

Insufficient new directors

Tabula Rasa Healthcare, Inc. Announces Results of Two Peer-Reviewed Studies That Explore Potential for Drug Interactions Among Those Who Use Opioids and Take Multiple Medications

Why Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Could Be Worth Watching

Insufficient new directors

Co-Founder recently sold US$2.9m worth of stock

Third quarter 2021 earnings released: US$0.73 loss per share (vs US$0.99 loss in 3Q 2020)

Price target decreased to US$46.71

Is Tabula Rasa HealthCare (NASDAQ:TRHC) A Risky Investment?

Tabula Rasa and Hesperos Receive $1.9 Million National Institutes of Health Award for Research Focused on Preventable Drug-Induced Alzheimer's Disease

Chief Operating Officer recently sold US$90k worth of stock

Second quarter 2021 earnings released: US$0.91 loss per share (vs US$0.66 loss in 2Q 2020)

Tabula Rasa Healthcare, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2021 and Year Ending December 31, 2021

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Chief Operating Officer exercised options and sold US$324k worth of stock

Tabula Rasa HealthCare, Inc. Enhances PrescribeWellness Software with MedWise Risk Level™

We Discuss Why Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) CEO Compensation May Be Closely Reviewed

Lead Independent Director exercised options and sold US$383k worth of stock

Tabula Rasa Healthcare, Inc. Announces Results of Simulation-Based Clinical Study which Demonstrates its MedWise® Medication Risk Score can be Used to Assess Drug Safety without Exposing Real People to Actual Harm

First quarter 2021 earnings released: US$0.85 loss per share (vs US$0.68 loss in 1Q 2020)